[go: up one dir, main page]

MX2012003398A - Agonistas npr-b novedosos. - Google Patents

Agonistas npr-b novedosos.

Info

Publication number
MX2012003398A
MX2012003398A MX2012003398A MX2012003398A MX2012003398A MX 2012003398 A MX2012003398 A MX 2012003398A MX 2012003398 A MX2012003398 A MX 2012003398A MX 2012003398 A MX2012003398 A MX 2012003398A MX 2012003398 A MX2012003398 A MX 2012003398A
Authority
MX
Mexico
Prior art keywords
agonists
npr
new
new npr
unconventional
Prior art date
Application number
MX2012003398A
Other languages
English (en)
Inventor
Gerd Hummel
Frank Osterkamp
Heiko Hawlisch
Tobias Knaute
Ulf Reimer
Ulrich Reineke
Uwe Richter
Bernadett Simon
Markus Woischnik
Mark R Hellberg
Edgar Specker
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43781057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012003398(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of MX2012003398A publication Critical patent/MX2012003398A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen compuestos novedosos que tienen actividad agonista de NPR-B. Los compuestos preferidos son péptidos lineales que contienen de 8-13 residuos de L o D aminoácidos convencionales o no convencionales conectados entre sí mediante enlaces de péptido.
MX2012003398A 2009-09-25 2010-09-23 Agonistas npr-b novedosos. MX2012003398A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24596009P 2009-09-25 2009-09-25
PCT/US2010/049912 WO2011038061A2 (en) 2009-09-25 2010-09-23 Novel npr-b agonists

Publications (1)

Publication Number Publication Date
MX2012003398A true MX2012003398A (es) 2012-04-10

Family

ID=43781057

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014001528A MX354005B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.
MX2017012681A MX370645B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.
MX2012003398A MX2012003398A (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2014001528A MX354005B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.
MX2017012681A MX370645B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.

Country Status (17)

Country Link
US (5) US8546523B2 (es)
EP (1) EP2480247B1 (es)
JP (3) JP5893561B2 (es)
KR (3) KR20180049198A (es)
CN (2) CN102548574B (es)
AR (1) AR078445A1 (es)
AU (1) AU2010298256B2 (es)
BR (1) BR112012006579A2 (es)
CA (1) CA2773949C (es)
CL (2) CL2012000715A1 (es)
MX (3) MX354005B (es)
PH (1) PH12012500562A1 (es)
RU (3) RU2636738C2 (es)
TW (2) TWI625126B (es)
UY (1) UY32902A (es)
WO (1) WO2011038061A2 (es)
ZA (3) ZA201201630B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2510942E (pt) 2005-04-07 2015-12-28 Cardiorentis Ag Utilização de péptido natriurético para o tratamento de insuficiência cardíaca
JP5345532B2 (ja) * 2006-08-02 2013-11-20 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ Ｌｃｔ中毒に対する医薬品
KR20180049198A (ko) * 2009-09-25 2018-05-10 샤이어 오펀 테라피즈 게엠베하 신규한 ｎｐｒ－ｂ 길항제
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.
CN104039341A (zh) * 2011-12-16 2014-09-10 卡乐斯治疗公司 用于治疗视网膜病症和疾病的anp(心钠素)、bnp(脑钠素)以及cnp(c型利钠肽)相关肽及其衍生物的方法和用途
EA201500765A1 (ru) * 2013-01-25 2015-12-30 Кардиорентис Лтд. Способы лечения сердечно-сосудистых заболеваний
CN116731101A (zh) 2016-06-01 2023-09-12 雅斯娜 用于治疗多种疾病的n-己酸-l-酪氨酸-l-异亮氨酸-(6)-氨基己酰胺的衍生物
WO2018144742A1 (en) 2017-02-01 2018-08-09 Shire Human Genetic Therapies, Inc. Compounds and compositions for the treatment of ophthalmic disorders
EP3810082A1 (en) * 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
UY38476A (es) * 2018-11-16 2020-06-30 Arcus Biosciences Inc Inhibidores de arg1 y/o arg2
CN115803338A (zh) * 2020-06-12 2023-03-14 药明公司 C型利尿钠肽及其治疗急性肺损伤的方法
KR102677730B1 (ko) * 2023-03-27 2024-06-27 나인바이오팜 주식회사 지방 분해 효능을 갖는 펩타이드 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
JP2855143B2 (ja) * 1987-12-24 1999-02-10 サイオス インコーポレイテッド 心房の，ナトリウム排出亢進性ペプチドの直鎖アナログ
JP2848411B2 (ja) * 1988-08-18 1999-01-20 サイオス インコーポレイテッド 心房性ナトリウム利尿ペプチドクリアランス阻害剤
KR100691545B1 (ko) 1998-09-28 2007-03-09 산텐 세이야꾸 가부시키가이샤 나트륨 이뇨 펩티드를 유효 성분으로하는 누액 분비 촉진또는 각결막 장해 치료용 점안제
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
ATE496060T1 (de) 2004-07-15 2011-02-15 Univ Queensland Proteinartige verbindungen und anwendungen davon
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20090035287A1 (en) * 2005-09-26 2009-02-05 Zurit Levine Atrial natriuretic peptide (anp) splice variants and methods of using same
CA2625600A1 (en) * 2005-10-14 2007-04-26 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
WO2007115182A2 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
EP2001518B1 (en) * 2006-03-30 2013-07-10 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
AU2008326327A1 (en) * 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
KR20180049198A (ko) 2009-09-25 2018-05-10 샤이어 오펀 테라피즈 게엠베하 신규한 ｎｐｒ－ｂ 길항제
WO2011038066A2 (en) 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.

Also Published As

Publication number Publication date
US20160194357A1 (en) 2016-07-07
CL2012000715A1 (es) 2012-11-30
TW201630619A (zh) 2016-09-01
CL2017001190A1 (es) 2017-12-01
RU2012116531A (ru) 2013-10-27
CN102548574A (zh) 2012-07-04
KR101768661B1 (ko) 2017-08-16
EP2480247B1 (en) 2020-02-12
RU2557290C2 (ru) 2015-07-20
TWI577384B (zh) 2017-04-11
KR20180049198A (ko) 2018-05-10
CA2773949C (en) 2020-11-03
JP6211032B2 (ja) 2017-10-11
US9982016B2 (en) 2018-05-29
WO2011038061A2 (en) 2011-03-31
TW201110974A (en) 2011-04-01
AU2010298256A1 (en) 2012-04-12
US20180334477A1 (en) 2018-11-22
MX354005B (es) 2018-02-08
US8546523B2 (en) 2013-10-01
KR20170094564A (ko) 2017-08-18
KR101854820B1 (ko) 2018-05-04
CA2773949A1 (en) 2011-03-31
EP2480247A4 (en) 2013-09-04
UY32902A (es) 2011-02-28
AU2010298256B2 (en) 2015-08-13
US9745344B2 (en) 2017-08-29
RU2017139870A3 (es) 2019-05-16
US10196423B2 (en) 2019-02-05
JP2013505937A (ja) 2013-02-21
ZA201702958B (en) 2018-08-29
RU2015124607A (ru) 2015-12-10
RU2636738C2 (ru) 2017-11-28
TWI625126B (zh) 2018-06-01
MX370645B (es) 2019-12-19
CN102548574B (zh) 2016-03-23
RU2017139870A (ru) 2019-05-16
US20110077381A1 (en) 2011-03-31
US20130345394A1 (en) 2013-12-26
KR20120091110A (ko) 2012-08-17
JP2017137362A (ja) 2017-08-10
CN105732767A (zh) 2016-07-06
PH12012500562A1 (en) 2012-10-22
EP2480247A2 (en) 2012-08-01
WO2011038061A3 (en) 2011-07-28
ZA201401625B (en) 2018-08-25
ZA201201630B (en) 2014-05-28
US20170313743A1 (en) 2017-11-02
JP5893561B2 (ja) 2016-03-23
US9169293B2 (en) 2015-10-27
BR112012006579A2 (pt) 2016-11-22
AR078445A1 (es) 2011-11-09
JP2015131856A (ja) 2015-07-23

Similar Documents

Publication Publication Date Title
MX2012003398A (es) Agonistas npr-b novedosos.
CL2012002884A1 (es) Polipeptido que comprende un dominio decimo de fibronectina de tipo iii que se unen a la proteina covertasa subtilisina kexina tipo q ( pcsk9); composicion farmacéutica que comprende dicho polipeptido.
CY1122794T1 (el) Συνθεσεις αλφα-γαλακτοσιδασης
CO6290770A2 (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
BR112012024373A2 (pt) peptídeos e métodos para sua preparação e uso.
AR087070A1 (es) Proteinas de fusion liberadoras de relaxina y usos de las mismas
JOP20200039A1 (ar) مُستحضر صيدلي يشتمل على hcg مأشوب
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
MX2010004298A (es) Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
EA201171494A1 (ru) Миметики белка smac
CL2011002036A1 (es) Analogo peptidico doble agonista de los receptores de glp-1 y de glucagon.
EA201390182A1 (ru) Соединения-агонисты рецептора glp-1, содержащие стабилизированные области
IL216718A0 (en) Improved reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c)
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
UA106586C2 (uk) Анти-cd79b антитіла, і імунокон'югати та способи їх застосування
PH12013501656A1 (en) Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
UA118167C2 (uk) Пептид та його застосування
PH12013500167A1 (en) Polypeptidic tyrosinase inhibitor
EA201290542A1 (ru) Модифицированные свиные соматотропиновые полипептиды и их применение
CO2018012258A2 (es) Compuestos de mic-1 y usos de estos
WO2011146922A3 (en) Materials and methods for treatment of inflammation
EP2819682A4 (en) TOPICAL GELS WITH ALPHA CONNEXIN C TERMINALS PEPTIDES (ACT)
EA201290541A1 (ru) Модифицированные бычьи соматотропиновые полипептиды и их применение
BR112018013071A2 (pt) uso de derivados de triptofano para formulações de proteínas
EA201190274A1 (ru) Конструкции casb7439

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: SHIRE ORPHAN THERAPIES GMBH